Half of adults with MCL who took Jaypirca saw their cancer shrink and stop spreading
Jaypirca was studied in a clinical trial that included people with mantle cell lymphoma (MCL) that came back or did not respond to previous treatment, and who had already received one or more treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine. The trial evaluated 120 people for their response to treatment (a response means their cancer shrank or stopped spreading) and how long the response lasted. People in the trial took Jaypirca once daily until their disease got worse or they were no longer able to tolerate treatment.
Half of adults who took Jaypirca saw a response to treatment and had fewer signs of the disease on their scans
In a clinical trial that measured the number of people who responded to treatment and how long the response lasted:
of adults with MCL (60 out of 120) saw their cancer shrink and stop spreading while taking Jaypirca
Of the 50%:
of adults (15 out of 120) had a complete response, which means scans and other tests showed no detectable signs of MCL
of adults (45 out of 120) had a partial response, which means scans and other tests showed their MCL shrank in response to treatment
- 65% were still responding to treatment at 6 months
- For those who saw their MCL shrink and stop spreading, their response lasted a median* of 8.3 months
*Median is the middle number in a range of numbers.
SELECT SAFETY INFORMATION
Warnings - Jaypirca may cause serious side effects, including:
Decrease in blood cell counts (cytopenia). Decrease in white blood cells, platelets, and red blood cells is common with Jaypirca but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your doctor will do blood tests regularly during treatment to monitor your counts.
In a clinical trial, Jaypirca started working quickly, with some people seeing their cancer reduce in size and stop spreading as soon as 7 to 8 weeks after starting treatment†
†In a clinical trial of Jaypirca, the median time for the cancer to shrink and stop spreading with treatment was 1.8 months, ranging from 3.5 weeks at the lowest to 4.2 months at the highest. Median is the middle number in a range of numbers ordered from lowest to highest.